↓ Skip to main content

Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19

Overview of attention for article published in Frontiers in immunology, September 2024
Altmetric Badge

Mentioned by

reddit
2 Redditors
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19
Published in
Frontiers in immunology, September 2024
DOI 10.3389/fimmu.2024.1420463
Authors

Qiaoyan Si, Mingjian Bai, Xiaolong Wang, Tianyu Wang, Yan Qin

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 August 2024.
All research outputs
#21,451,622
of 26,411,386 outputs
Outputs from Frontiers in immunology
#26,053
of 33,432 outputs
Outputs of similar age
#104,304
of 162,505 outputs
Outputs of similar age from Frontiers in immunology
#206
of 361 outputs
Altmetric has tracked 26,411,386 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 33,432 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 162,505 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 361 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.